Oxular
Manufacturing · Wisconsin, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Robert Robinson Ave, Oxford, Wisconsin...Phone Number
+44 1865636200Website
www.oxular.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Oxular
Oxular is a retinal therapeutics development company. Oxular combines proprietary drug formulation and ocular administration technology to transform treatments for retinal diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oxular your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Oxular had a recent Job posting/layoffs
Earning: See what the market has to say on Oxular recently announced quarterly report
Oxular, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Oxular launches new products
Congratulate Masked Content for being promoted to Masked Content at Oxular
Check out if Oxular is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Oxular has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Oxular has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Oxular as Masked Content
Find 3 more new buyers
Compare Similar Companies to Oxular
Compare insights from companies similar to Oxular, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Oxular
<$5M
11-50
Private
$37M
2014
N/A
Company Profile Activity
Activity Insights
Oxular is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oxular is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oxular.
Oxular financials insights
Gather financial insights about Oxular, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$37M
Oxular Tech Stack
A closer look at the technologies used by Oxular
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Oxular has announced that Mark Gaffney has joined the organization as Chief Executive Officer. Previously, Gaffney served as Chief Operating Officer at Vedere Bio II.
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Oxular News & Media
Oxular Announces Appointment of Mark Gaffney as Chief Executive Officer
OXFORD, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announces that Mark Gaffney has been appointed as chief executive officer (CEO) and member of the Board of Directors. Mr. Gaffney succeeds Thomas Cavanagh, who has transitioned from his role as CEO role to pursue other opportunities. “This is an exciting time of clinical development atOxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema
OXFORD, United Kingdom--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND enables advancement of the OXEYE Phase 2 trial, which will evaluate the safety and efficacy of OXU-001 andOxular Limited Appoints Industry Veteran James Jogerst as Chief Business Officer
OXFORD, England--(BUSINESS WIRE)--Oxular Limited, a clinical-stage retinal therapeutics company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced the appointment of James “Jim” Jogerst as chief business officer, who will lead the company’s business development strategy, and oversee its current and planned strategic partnerships. Mr. Jogerst joins Oxular from Rubius Therapeutics, where he served as chief business officer. “We are thril
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oxular
Sign Up For FreeTo access detailed company insights
Oxular is a retinal therapeutics development company. Oxular combines proprietary drug formulation and ocular administration technology to transform treatments for retinal diseases.... Read More
